Premium
Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression
Author(s) -
Boggio Paulo S.,
Fregni Felipe,
Bermpohl Felix,
Mansur Carlos G.,
Rosa Moacyr,
Rumi Demetrio O.,
Barbosa Egberto R.,
Odebrecht Rosa Marina,
PascualLeone Alvaro,
Rigonatti Sérgio Paulo,
Marcolin Marco A.,
Araujo Silva Maria Teresa
Publication year - 2005
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20508
Subject(s) - fluoxetine , transcranial magnetic stimulation , stroop effect , psychology , context (archaeology) , parkinson's disease , major depressive disorder , neuropsychology , depression (economics) , cognition , deep transcranial magnetic stimulation , psychiatry , medicine , neuroscience , disease , stimulation , paleontology , receptor , macroeconomics , serotonin , economics , biology
Previous studies show that cognitive functions are more impaired in patients with Parkinson's disease (PD) and depression than in nondepressed PD patients. We compared the cognitive effects of two types of antidepressant treatments in PD patients: fluoxetine (20 mg/day) versus repetitive transcranial magnetic stimulation (rTMS, 15 Hz, 110% above motor threshold, 10 daily sessions) of the left dorsolateral prefrontal cortex. Twenty‐five patients with PD and depression were randomly assigned either to Group 1 (active rTMS and placebo medication) or to Group 2 (sham rTMS and fluoxetine). A neuropsychological battery was assessed by a rater blind to treatment arm at baseline and 2 and 8 weeks after treatment. Patients in both groups had a significant improvement of Stroop (colored words and interference card) and Hooper and Wisconsin (perseverative errors) test performances after both treatments. Furthermore, there were no adverse effects after either rTMS or fluoxetine in any neuropsychological test of the cognitive test battery. The results show that rTMS could improve some aspects of cognition in PD patients similar to that of fluoxetine. The mechanisms for this cognitive improvement are unclear, but it is in the context of mood improvement. © 2005 Movement Disorder Society